Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Darunavir (Prezista®) 100 mg/ml oral suspension, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales, in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients, as well as antiretroviral therapy-experienced paediatric patients from the age of 3 years and at least 15 kg body weight. |
|||
|
|||
Medicine details |
|||
| Medicine name | darunavir (Prezista®) | ||
| Formulation | 100 mg/ml oral suspension | ||
| Reference number | 1383 | ||
| Indication | Co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients, as well as antiretroviral therapy-experienced paediatric patients from the age of 3 years and at least 15 kg body weight |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1213 | ||
| NMG meeting date | 10/04/2013 | ||
| AWMSG meeting date | 08/05/2013 | ||
| Ratification by Welsh Government | 29/07/2013 | ||
| Date of issue | 31/07/2013 | ||
| Date of last review | November 2022 | ||
| Further information This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||